Observational studies suggest that obesity is associated with increased MS disease activity, greater disability progression, and potentially reduced response to some disease-modifying therapies, though causality has not been established
Product Specifications Form: Lyophilized powder Amount: 10mg total (5mg CJC-1295 No DAC + 5mg Ipamorelin) Purity: 98% Appearance: White to off-white powder Molecular Information CJC-1295 No DAC Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Gly-Ser Ipamorelin Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH CAS (CJC-1295 No DAC): 863288-34-0 CAS (Ipamorelin): 170851-70-4 Research Applications Peptide-receptor interaction research Cellular signaling pathway investigations Neuroendocrine pathway research models Multi-peptide interaction studies in controlled laboratory environments Storage Store lyophilized material in a cool, dry environment
Semaglutide is a GLP-1 (Glucagon-Like Peptide-1) receptor agonist, a class of medication initially developed for managing Type 2 diabetes
Curr Opin Pharmacol 7:355359
Participants maintained weight loss with continued semaglutide use, and cardiovascular events, death, and serious adverse events were comparable to or lower than the placebo group
